RDY
Dr. Reddy’s Laboratories Ltd ADR
NYSE: RDY · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$14.15
+2.91% today
Updated 2026-10-28
Market cap
$11.00B
P/E ratio
36.69
P/S ratio
0.03x
EPS (TTM)
$0.36
Dividend yield
0.63%
52W range
$11 – $15
Volume
3.0M
Dr. Reddy’s Laboratories Ltd ADR (RDY) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$14.15
12-Month target
$13.43
2030 Target
$20.95
Intrinsic (DCF)
—
Financial forecast
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $214.4B | $245.9B | $279.2B | $325.5B | $353.5B | $424.2B | $509.0B | $610.8B | $733.0B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 20.00% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 8.49%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.